Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up

Haematologica. 2024 Jul 1;109(7):2359-2363. doi: 10.3324/haematol.2024.285207.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating / adverse effects
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Cancer Survivors
  • Central Nervous System Neoplasms* / drug therapy
  • Central Nervous System Neoplasms* / mortality
  • Dacarbazine / administration & dosage
  • Dacarbazine / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma / drug therapy
  • Lymphoma / mortality
  • Maintenance Chemotherapy
  • Male
  • Middle Aged
  • Temozolomide* / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Temozolomide

Grants and funding

Funding: This work was funded by grants from Nordic Cancer Union, Norpharma, Roche, Schering-Plough, and Inge og Jørgen Larsens Mindelegat.